| Name | Title | Contact Details |
|---|
For more than 25 years we`ve been helping remove pain and discomfort from people`s lives. Our patients trust in our expertise` which is why 98 percent would recommend us to a friend – because we were able to help make their lives better. – Athletico Physical Therapy` Better for Every Body. Athletico Physical Therapy provides the highest quality orthopedic rehabilitation services to communities` employers and athletes` with over 450 locations throughout twelve states. To demonstrate our commitment to both our patients and referring physicians` we measure functional patient outcomes and patient satisfaction with national data comparison using a third-party outcomes system. Our services include physical and occupational/hand therapy` work rehabilitation` women`s health therapy` pediatric physical therapy` concussion management and athletic training. Athletico has staff with expertise in treating the worker`s compensation population with such services as work conditioning and functional capacity evaluations. In addition` Athletico provides athletic training` physical and occupational therapy` and fitness services to over 150 affiliations including high schools` colleges` and many of Chicago`s professional sports teams.
Ambry Genetics is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Sarasota Home Health Care Agency is a Osprey, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lumeris is a value-based care managed services operator for health systems and providers seeking extraordinary clinical and financial outcomes. Lumeris aligns providers and payers across populations with technologies, processes, behaviors and information to achieve high-quality, cost-effective care with satisfied consumers — and engaged physicians. Lumeris with Essence Healthcare, its inaugural client with more than 60,000 Medicare members in Missouri and Illinois, has averaged a CMS rating of 4.5 Stars for the last ten years and produced the highest consumer and physician satisfaction scores in the industry along with significantly better clinical outcomes and lower costs.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.